WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 314273

CAS#: 162011-90-7

Description: Rofecoxib is a nonsteroidal anti-inflammatory drug (NSAID) that has now been withdrawn over safety concerns. Rofecoxib exhibits anti-inflammatory, analgesic, and antipyretic activities in animal models. The mechanism of action of rofecoxib is believed to be due to inhibition of prostaglandin synthesis, via inhibition of cyclooxygenase-2 (COX-2). At therapeutic concentrations in humans, rofecoxib does not inhibit the cyclooxygenase-1 (COX-1) isoenzyme. Studies to elucidate the mechanism of action of fofecoxib in the acute treatment of migraine have not been conducted.

Chemical Structure

CAS# 162011-90-7

Theoretical Analysis

MedKoo Cat#: 314273
Name: Rofecoxib
CAS#: 162011-90-7
Chemical Formula: C17H14O4S
Exact Mass: 314.06128
Molecular Weight: 314.36
Elemental Analysis: C, 64.95; H, 4.49; O, 20.36; S, 10.20

Price and Availability

Size Price Availability Quantity
250.0mg USD 150.0 2 Weeks
500.0mg USD 250.0 2 Weeks
1.0g USD 450.0 2 Weeks
2.0g USD 750.0 2 Weeks
5.0g USD 1550.0 2 Weeks
Bulk inquiry

Synonym: MK966; MK966; MK 966; MK0966; MK0966; MK 0966; Rofecoxib; brand name: Vioxx; Ceoxx; Ceeoxx.

IUPAC/Chemical Name: 4-(4-(methylsulfonyl)phenyl)-3-phenylfuran-2(5H)-one


InChi Code: InChI=1S/C17H14O4S/c1-22(19,20)14-9-7-12(8-10-14)15-11-21-17(18)16(15)13-5-3-2-4-6-13/h2-10H,11H2,1H3

SMILES Code: O=C1C(C2=CC=CC=C2)=C(C3=CC=C(S(=O)(C)=O)C=C3)CO1

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO.

Shelf Life: >2 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

Preparing Stock Solutions

The following data is based on the product molecular weight 314.36 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.


Dilution Calculator

Calculate the dilution required to prepare a stock solution.

 1: Rahme E, Roussy JP, Lafrance JP, Nedjar H, Morin S. Use of nonsteroidal antiinflammatory drugs: is there a change in patient risk profile after withdrawal of rofecoxib? J Rheumatol. 2011 Feb;38(2):195-202. doi: 10.3899/jrheum.100332. Epub 2010 Nov 15. Review. PubMed PMID: 21078717.

2: Bulley S, Derry S, Moore RA, McQuay HJ. Single dose oral rofecoxib for acute postoperative pain in adults. Cochrane Database Syst Rev. 2009 Oct 7;(4):CD004604. doi: 10.1002/14651858.CD004604.pub3. Review. PubMed PMID: 19821329; PubMed Central PMCID: PMC4171390.

3: Jaksch W, Dejaco C, Schirmer M. 4 years after withdrawal of rofecoxib: where do we stand today? Rheumatol Int. 2008 Oct;28(12):1187-95. doi: 10.1007/s00296-008-0650-4. Epub 2008 Jul 29. Review. PubMed PMID: 18663451.

4: Chen YF, Jobanputra P, Barton P, Bryan S, Fry-Smith A, Harris G, Taylor RS. Cyclooxygenase-2 selective non-steroidal anti-inflammatory drugs (etodolac, meloxicam, celecoxib, rofecoxib, etoricoxib, valdecoxib and lumiracoxib) for osteoarthritis and rheumatoid arthritis: a systematic review and economic evaluation. Health Technol Assess. 2008 Apr;12(11):1-278, iii. Review. PubMed PMID: 18405470.

5: Mason RP, Walter MF, Day CA, Jacob RF. A biological rationale for the cardiotoxic effects of rofecoxib: comparative analysis with other COX-2 selective agents and NSAids. Subcell Biochem. 2007;42:175-90. Review. PubMed PMID: 17612051.

6: Burnier M. The safety of rofecoxib. Expert Opin Drug Saf. 2005 May;4(3):491-9. Review. PubMed PMID: 15934855.

7: Krymchantowski AV, Bigal ME. Rofecoxib in migraine. Expert Rev Neurother. 2005 Jan;5(1):55-61. Review. PubMed PMID: 15853474.

8: Marshall LL. Angioedema associated with aspirin and rofecoxib. Ann Pharmacother. 2005 May;39(5):944-8. Epub 2005 Apr 5. Review. PubMed PMID: 15811906.

9: Barden J, Edwards J, Moore RA, McQuay HJ. Single dose oral rofecoxib for postoperative pain. Cochrane Database Syst Rev. 2005 Jan 25;(1):CD004604. Review. Update in: Cochrane Database Syst Rev. 2009;(4):CD004604. PubMed PMID: 15674955.

10: Garner SE, Fidan DD, Frankish RR, Judd MG, Towheed TE, Wells G, Tugwell P. Rofecoxib for rheumatoid arthritis. Cochrane Database Syst Rev. 2005 Jan 25;(1):CD003685. Review. PubMed PMID: 15674912.

11: Garner SE, Fidan DD, Frankish R, Maxwell L. Rofecoxib for osteoarthritis. Cochrane Database Syst Rev. 2005 Jan 25;(1):CD005115. Review. PubMed PMID: 15654705.

12: Scheen AJ. [Withdrawal of rofecoxib (Vioxx): what about cardiovascular safety of COX-2 selective non-steroidal anti-inflammatory drugs?]. Rev Med Liege. 2004 Oct;59(10):565-9. Review. French. PubMed PMID: 15623076.

13: Lizán Tudela L, Magaz Marqués S, Varela Moreno C, Riesgo Bucher Y. [Analysis of cost-minimization treatment with paracetamol or COX-2 inhibitors (rofecoxib) for pain from arthrosis of the knee or hip]. Aten Primaria. 2004 Dec;34(10):534-40. Review. Spanish. PubMed PMID: 15607056.

14: Szalat A, Krasilnikov I, Bloch A, Meir K, Rubinger D, Mevorach D. Acute renal failure and interstitial nephritis in a patient treated with rofecoxib: case report and review of the literature. Arthritis Rheum. 2004 Aug 15;51(4):670-3. Review. PubMed PMID: 15334443.

15: Barden J, Edwards J, Moore RA, McQuay HJ. Single dose oral rofecoxib for postoperative pain. Cochrane Database Syst Rev. 2004;(1):CD004604. Review. Update in: Cochrane Database Syst Rev. 2005;(1):CD004604. PubMed PMID: 14974074.

16: Schmidt H, Woodcock BG, Geisslinger G. Benefit-risk assessment of rofecoxib in the treatment of osteoarthritis. Drug Saf. 2004;27(3):185-96. Review. PubMed PMID: 14756580.

17: Phelan KM, Mosholder AD, Lu S. Lithium interaction with the cyclooxygenase 2 inhibitors rofecoxib and celecoxib and other nonsteroidal anti-inflammatory drugs. J Clin Psychiatry. 2003 Nov;64(11):1328-34. Review. PubMed PMID: 14658947.

18: Coulter DM, Clark DW, Savage RL. Celecoxib, rofecoxib, and acute temporary visual impairment. BMJ. 2003 Nov 22;327(7425):1214-5. Review. PubMed PMID: 14630760; PubMed Central PMCID: PMC274063.

19: Weir MR, Sperling RS, Reicin A, Gertz BJ. Selective COX-2 inhibition and cardiovascular effects: a review of the rofecoxib development program. Am Heart J. 2003 Oct;146(4):591-604. Review. PubMed PMID: 14564311.

20: Ahuja N, Singh A, Singh B. Rofecoxib: an update on physicochemical, pharmaceutical, pharmacodynamic and pharmacokinetic aspects. J Pharm Pharmacol. 2003 Jul;55(7):859-94. Review. PubMed PMID: 12906745.


250.0mg / USD 150.0